Wednesday, March 4, 2015

Synergy Disc Replacement sets global sales plan

Synergy Disc Replacement sets global sales plan

March 3, 2015 by · Leave a Comment 

Tweet After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution aggressively in Europe, Asia Pacific and other parts of the world. “We are also in the early stages of developing our U.S. regulatory strategy to gain […]

Dipexium passes 25% enrollment in Locilex Phase 3s

Dipexium passes 25% enrollment in Locilex Phase 3s

February 25, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, have passed the 25% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. The OneStep Phase 3 clinical trials are being conducted under a FDA from the FDA for evaluation of Locilex (pexiganan cream 0.8%), […]

Highland starts Columbia Labs at buy

Highland starts Columbia Labs at buy

February 25, 2015 by · Leave a Comment 

Tweet Highland Research Advisors has initiated coverage of Columbia Laboratories (NASDAQ:CBRX) with a “buy” rating and price target of $14. The stock closed at $6.05 on Tuesday. Columbia is focused on developing products to address the healthcare needs of women and has received FDA approval for six products, including Crinone, a gel containing progesterone that […]

Canaccord starts Avinger at buy

Canaccord starts Avinger at buy

February 24, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Avinger (NASDAQ:AVGR) with a “buy” rating and price target of $18. The stock closed at $10.66 on Monday. “Avinger checks the most important boxes that we look for in a small-cap med-tech growth stock,” writes analyst Jason Mills. He said Avinger targets a large, under-penetrated and growing addressable […]

Dipexium has positive skin sensitization data with Locilex

Dipexium has positive skin sensitization data with Locilex

February 17, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) has announced successful completion and initial results of DPX-120, a Phase 1 skin sensitization trial of its broad-spectrum topical antibiotic peptide, Locilex. DPX-120 was a double-blind study in healthy adult subjects with the primary objective of evaluating the potential of Locilex cream to induce contact sensitization by repetitive application to human […]

Neovasc launching Reducer in Europe for RA

Neovasc launching Reducer in Europe for RA

February 17, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=LdK0CXdhgDo’]

Tweet Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. “Our aim is have distributors selling Reducer in Switzerland, Italy and the UK, while in Germany, we’ll use a combination of distributors and our own sales […]

Cantor starts Pernix Therapeutics at buy

Cantor starts Pernix Therapeutics at buy

February 10, 2015 by · Leave a Comment 

Tweet Cantor Fitzgerald has initiated coverage of Pernix Therapeutics (NASDAQ:PTX) with a “buy” rating and $11 price target. The stock closed at $8.17 on Monday. Pernix is a specialty pharma company that is actively rebuilding its asset base after a significant corporate restructuring process in 2014. The base business consists of Treximet, a unique combination […]

Amarantus eltoprazine PD data published

Amarantus eltoprazine PD data published

February 10, 2015 by · Leave a Comment 

Tweet Amarantus BioSciences Holdings (OTCQB:AMBS) announced the publication of results of a Phase 2a study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesias (PD-LID). The paper titled, “Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson’s disease: A Dose-Finding Study,” has been published in Oxford Journals (Oxford University Press) online and will appear shortly in a future print edition […]

Janney starts Insmed at buy

Janney starts Insmed at buy

February 9, 2015 by · Leave a Comment 

Tweet Janney Capital Markets has initiated coverage of Insmed (NASDAQ:INSM) with a “buy” rating and fair value estimated of $33. The stock closed at $15.44 on Monday. Lead product, Arikace, has the potential to be the first inhaled antibiotic for nontuberculous mycobacteria (NTM) lung infections. “Though negative culture conversion was not the original endpoint from […]

Dipexium advancing EU approval strategy for Locilex

Dipexium advancing EU approval strategy for Locilex

February 3, 2015 by · Leave a Comment 

Tweet With its Phase 3 program underway in the U.S., Dipexium (NASDAQ:DPRX) has begun the regulatory process with the European Medicines Agency (EMA) for its Locilex topical treatment for diabetic foot infections (DFI). “Our strategy is to seek approval for Locilex in Europe based solely on data from our U.S. clinical trials, without any need […]

Next Page »

Email Newsletters with Constant Contact
Google+